Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 15, 2001Journal of Clinical Oncology

Rituximab Dose-Escalation Trial in Chronic Lymphocytic Leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

Susan O’BrienSusan O’BrienBoston UniversityHagop M. KantarjianHagop M. KantarjianThe University of Texas MD Anderson Cancer CenterDTDeborah A. ThomasWesleyan University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

O’Brien et al. (2001) studied this question.

synapsesocial.com/papers/6a128f76ea48cb855a3515efhttps://doi.org/10.1200/jco.2001.19.8.2165
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Nonparametric Estimation from Incomplete Observations1958 · 39,556 citations
  2. 2Different mechanisms define the antiadhesive function of high molecular weight kininogen in integrin- and urokinase receptor–dependent interactions2000 · 93 citations
  3. 3National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment1996 · 1,830 citations
  4. 4Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia1992 · 177 citations
  5. 5Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.1998 · 2,771 citations